Trimetazidine Drug Interactions: What Is Known and What Is Not
Trimetazidine is a heart medication prescribed in Europe and many other countries but not approved in the United States. It reached American headlines mostly through doping cases in figure skating and other sports. Our editors reviewed what its labeling and the medical literature say about interactions with other drugs, and why the most important "interactions" are often with a patient's own health conditions.
What trimetazidine is and how it is handled by the body
Trimetazidine is classified as a metabolic anti-anginal agent. Unlike nitrates, beta-blockers or calcium channel blockers, it does not significantly change heart rate, blood pressure or coronary blood flow. Instead it alters how heart cells produce energy when oxygen is scarce.
Its main proposed mechanism, described by Kantor and colleagues in 2000, is partial inhibition of the mitochondrial enzyme long-chain 3-ketoacyl-CoA thiolase. This shifts cardiac metabolism away from fatty acid oxidation toward glucose oxidation, which yields more ATP per unit of oxygen consumed. In theory, this helps ischemic heart muscle cope with reduced blood supply.
From a pharmacokinetic standpoint, trimetazidine is absorbed well after oral intake and is eliminated largely unchanged in the urine. It is not heavily dependent on the liver's cytochrome P450 enzymes, which is why classic metabolic drug-drug interactions are uncommon compared with many cardiovascular medicines.
The kidney-based elimination, however, makes renal function the single most important factor for exposure. When kidney function declines, blood levels rise, and with them the risk of side effects. European labeling therefore restricts or adjusts its use in kidney impairment and in older adults.
Regulatory status in the US, Europe and sport
Trimetazidine has never been approved by the FDA, so it cannot legally be marketed as a prescription drug or a dietary supplement in the United States. Products containing it that appear online are unapproved drugs, and their quality and actual content are unknown.
In 2012 the European Medicines Agency completed a review that limited trimetazidine to add-on treatment of stable angina in patients who are inadequately controlled by, or intolerant to, first-line therapies. Indications in tinnitus, vertigo and visual disorders were withdrawn because the benefit was not shown to outweigh the risks.
The World Anti-Doping Agency added trimetazidine to its Prohibited List in 2014 and has since classified it among hormone and metabolic modulators, prohibited at all times. Athletes in US college and professional programs that follow WADA rules face sanctions if it is detected, regardless of the claimed reason, unless a therapeutic use exemption has been granted.
| Jurisdiction | Status | Practical meaning |
|---|---|---|
| United States (FDA) | Not approved | No legal prescription or supplement product |
| European Union (EMA) | Prescription only, restricted | Second-line add-on for stable angina |
| WADA / USADA | Prohibited at all times | Positive test leads to anti-doping violation |
The labeled adult dose of the modified-release form in Europe is 35 mg twice daily, with lower doses in moderate kidney impairment and in some elderly patients. These figures come from official labeling and are provided only as context; they are not recommendations for use.
Documented and theoretical drug interactions
European product information states that no clinically significant pharmacokinetic interactions have been identified in standard studies. Trimetazidine is commonly co-prescribed with beta-blockers, calcium channel blockers, nitrates, statins and antiplatelet agents in angina patients, and large trials such as ATPCI used it on top of such standard therapy.
The more relevant concerns are pharmacodynamic, meaning that two drugs add up to a combined effect rather than changing each other's blood levels. The best-known example involves movement disorders, discussed below. Another concern is additive lowering of blood pressure with antihypertensives, which the EMA linked to falls in older people.
- Drugs that can cause parkinsonism: antipsychotics, metoclopramide, some antiemetics; combined use may raise the risk of tremor or rigidity.
- Drugs that impair kidney function: NSAIDs, certain antibiotics, contrast agents; reduced clearance can increase trimetazidine exposure.
- Antihypertensives and sedatives: potential contribution to dizziness, unsteady gait and falls.
- Other metabolic modulators: combining with substances such as meldonium has no established medical rationale and no safety data.
Interactions with dietary supplements have not been systematically studied. That absence of data is not the same as proof of safety, particularly for products of unknown composition purchased outside the regulated pharmacy system.
Movement disorders and kidney function: the key cautions
The most important safety signal for trimetazidine is drug-induced parkinsonism and related movement disorders: tremor, rigidity, slowed movement, gait instability and restless legs. A French pharmacovigilance case series by Masmoudi and colleagues (2012) described such reactions, most of which resolved after the drug was stopped, though recovery sometimes took months.
Because of this, European labeling contraindicates trimetazidine in people with Parkinson's disease, parkinsonian symptoms, tremor, restless legs syndrome and other related movement disorders. The risk appears higher in older patients and in those with reduced kidney function, where drug levels are higher.
Severe kidney impairment (creatinine clearance below 30 mL/min) is a contraindication in European labeling, and moderate impairment requires a reduced dose. Any drug that acutely worsens kidney function, including dehydration in an athlete or high-dose NSAID use, can therefore indirectly turn a tolerated regimen into a risky one.
Other reported adverse effects include gastrointestinal discomfort, headache, dizziness, skin reactions and, rarely, low platelet counts or liver enzyme changes. Anyone prescribed the drug abroad who develops new tremor or walking difficulties should contact a doctor promptly.
Why athletes should avoid self-experimentation
Interest in trimetazidine among athletes stems from the idea that shifting metabolism toward glucose could improve efficiency under stress. There is no robust evidence that it improves athletic performance in healthy people, and its effects were studied in patients with ischemic heart disease, not in trained individuals.
The doping risk is substantial. Trimetazidine is detectable in urine and has been involved in several high-profile anti-doping cases, including in minors. Contamination of supplements and medications is also possible, which is one reason why the strict liability principle in anti-doping rules makes careful product selection essential.
Unregulated online sources add further danger: wrong dose, mislabeled content or impurities. Combining an unknown product with prescription medicines, alcohol or other stimulants makes any interaction impossible to predict.
Athletes with genuine chest pain or exercise intolerance need a cardiology evaluation, not a metabolic drug borrowed from another country's formulary. Many serious cardiac conditions in young athletes present first as unexplained fatigue or breathlessness.
Conclusions of the editorial team
Trimetazidine has relatively few classic pharmacokinetic drug interactions, but its safety depends heavily on kidney function, age and coexisting movement disorders.
The most clinically relevant combination risks involve drugs that cause parkinsonism, drugs that impair kidney function and agents that lower blood pressure. In sport, it is a prohibited substance with no proven benefit for healthy athletes.
Readers may also find value in our articles on meldonium and other metabolic modulators, on NSAIDs and kidney health in athletes, and on how therapeutic use exemptions work.
References
- Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86(5):580–588.
- Masmoudi K, Masson H, Gras V, Andréjak M. Extrapyramidal adverse drug reactions associated with trimetazidine: a series of 21 cases. Fundam Clin Pharmacol. 2012;26(2):198–203.
- Ferrari R, Ford I, Fox K, et al. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;396(10254):830–838.
- Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–477.
- European Medicines Agency. Questions and answers on the review of medicines containing trimetazidine. London: EMA; 2012.
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2025. Montreal: WADA; 2025.
